AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BLSM · NASDAQ · Biotechnology

BlossomHill Therapeutics (BLSM)

Develops oral small-molecule cancer therapies for EGFR, CLK and KRAS targets.

$19.38

Pre-market+0.10 (+0.52%)

At close$19.28(+1.53%)

Watchlist

In millions of USD, except per-share figures

In millions	Q1 FY25Mar 2025	Q1 FY26Mar 2026
	11	22
Research & development	10	20
	2	2
General & administrative	2	2
Operating income	−11	−22
	1	1
Interest income	1	1
Income before tax	−10	−21
Net income from continuing operations	−10	−21
Net income	−10	−21
EPS, basic	−$0.36	−$0.72
EPS, diluted	−$0.36	−$0.72
Weighted average shares, basic	29	29
Weighted average shares, diluted	29	29
EBITDA	−11	−22
Depreciation & amortization	0	0
EBIT	−11	−22